Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Daxinganling Lingonberry Boreal Biotech, commonly referred to as Lgberry or LGB, is a China-based manufacturer of plant extracts, fruit-derived ingredients, natural colorants, customized formulation blends, and OEM services. The company appears to operate primarily in the nutraceutical, food ingredient, and health ingredient markets rather than as a therapeutic drug developer. Its product portfolio includes botanical extracts such as lutein, anthocyanins, arbutin, ursolic acid, oligomeric proanthocyanidines, frozen fruit products, concentrates, and powders. The business emphasizes sourcing from the Daxinganling region and highlights GMP-capable production, in-house R&D, and a patent portfolio. For biotech analysts, this is best categorized as a commercial natural products and health-ingredient manufacturer with some healthcare adjacency, not a clinical-stage biopharma company.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Daxinganling Lingonberry Boreal Biotech.